Wall Street Analysts See a 51.15% Upside in Liquidia Corporation (LQDA): Can the Stock Really Move This High?

The consensus price target hints at a 51.2% upside potential for Liquidia Corporation (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 24, 2025

Liquidia Corporation (LQDA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Liquidia Corporation ( LQDA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Hi, everyone, thanks so much for attending the Liquidia fireside chat. Day 2 of the conference, the weather in London is getting a little chilly, but it's good for staying awake.

Seeking Alpha • Nov 19, 2025

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch

California-based TCG Crossover Management added 1.7 million shares of Liquidia for an estimated $38.9 million in the third quarter. The position represented 1.9% of reported assets at quarter-end.

The Motley Fool • Nov 17, 2025

Wall Street Analysts Think Liquidia Corporation (LQDA) Could Surge 62.34%: Read This Before Placing a Bet

The consensus price target hints at a 62.3% upside potential for Liquidia Corporation (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 6, 2025

Liquidia Corporation: Heading In The Right Direction

Liquidia Corporation has just posted strong Q3 results after a recent FDA approval, and the commercial launch of YUTREPIA is showing solid early sales traction. The Q3 earnings beat has triggered numerous upward price target revisions for LQDA stock from analyst firms. Liquidia has a solid balance sheet and is well on its way to consistent profitability.

Seeking Alpha • Nov 5, 2025

Liquidia Corporation (LQDA) Q3 2025 Earnings Call Transcript

Liquidia Corporation ( LQDA ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Jason Adair - Chief Business Officer Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Scott Moomaw - Chief Commercial Officer Rajeev Saggar - Chief Medical Officer Russell Schundler - General Counsel & Corporate Secretary Conference Call Participants Amy Li - Jefferies LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Serge Belanger - Needham & Company, LLC, Research Division Andrew Fein - H.C. Wainwright & Co, LLC, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Liquidia Corporation Third Quarter 2025 Financial Results and Corporate Update Conference Call.

Seeking Alpha • Nov 3, 2025

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company's executive leadership team will be providing updates on the company's business during fireside chats at the following two investor conferences in November:

GlobeNewsWire • Nov 3, 2025

Liquidia Corporation (LQDA) Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies Transcript

Liquidia Corporation ( LQDA ) Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies October 28, 2025 2:00 PM EDT Company Participants Roger Jeffs - CEO & Director Rajeev Saggar - Chief Medical Officer Jason Adair - Chief Business Officer Conference Call Participants Richard Channick Rajan Saggar Ricardo Restrepo-Jaramillo Julian Harrison - BTIG, LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Pavan Patel - BofA Securities, Research Division Amy Li - Jefferies LLC, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Ryan Deschner - CGS International Presentation Roger Jeffs CEO & Director Well, great. Thank you, everybody, for being seated.

Seeking Alpha • Oct 29, 2025

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

GlobeNewsWire • Oct 27, 2025

Wall Street Analysts Believe LIQUIDIA CORP (LQDA) Could Rally 50.94%: Here's is How to Trade

The consensus price target hints at a 50.9% upside potential for LIQUIDIA CORP (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Oct 21, 2025